You might also like
Part 2: Clinical Case Study Compendium:
PDF case reports 3 & 4
The impact of gilteritinib in daily practice after intensive chemotherapy and following an allo-HSCT
View more
Clinical Case Study Compendium:
Video case report 5
Real-World Experiences by prof. dr. M. Beckers, UZ Leuven. Video of case report 5
View more
Article: The Role of Gilteritinib in the Treatment of Relapsed or Refractory FLT3-Mutated AML¹
Part I: first 2 case reports
Case report 1: gilteritinib as salvage treatment post Venetoclax-Azacitidine
Case report 2: gilteritinib as bridging therapy to allo HSCT2
Intended for: practitioners hematology
Why: up-to-date knowledge TKI3 related target therapy
When: read now
Language: English
Duration: 10 minutes
1: Acute Myeloid Leukemia; 2: Hematopoietic Stem Cell Transplantation; 3: Tyrosine Kinase Inhibitor.
MAT-BE-XOS-2025-00023 NOV 2025
AML: Acute Myeloid Leukemia
COPYRIGHT © 2026 ASTELLAS PHARMA B.V. MAT-BE-XOS-2025-00030 - DEC 2025